Tuesday, October 25, 2016 8:38:58 AM
For who owns the shares, contact the tranfer agent.
For clinical trial financing, contact Barry Hall or Mike Irving.
As for myself, I don't care who owns the shares and I don't care where they got the money for the clinical trials. The important thing is that the clinical trials are complete and results are due out soon.
As for "misdirection", would not modifying a Consumer Reports article to falsely implicate Roth be misdirection? How about an FDA youtube video that does not apply either?
I suggest that everyone keep their eye on the ball and watch for clinical trial results in the next couple weeks.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM